Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Futura Medical ( (GB:FUM) ) has shared an announcement.
Futura Medical plc announced that its directors and associated persons have subscribed for 6,000,000 new ordinary shares as part of a recent fundraising initiative. This move signifies strong internal confidence in the company’s growth prospects and aims to bolster its financial position to further develop and commercialize its innovative sexual health products, potentially strengthening its market position and delivering value to stakeholders.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and global commercialization of innovative and clinically proven sexual health products. Their lead product, Eroxon®, is a topical gel treatment for erectile dysfunction (ED) available over the counter. The company focuses on addressing significant unmet needs in the sexual health market, with products like Eroxon® and WSD4000, which is designed for women’s sexual dysfunction.
Average Trading Volume: 3,788,624
Technical Sentiment Signal: Sell
Current Market Cap: £5.93M
Find detailed analytics on FUM stock on TipRanks’ Stock Analysis page.